Search Results - "WHITE, Darrell"

Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study by Bahlis, Nizar J., Dimopoulos, Meletios A., White, Darrell J., Benboubker, Lotfi, Cook, Gordon, Leiba, Merav, Ho, P. Joy, Kim, Kihyun, Takezako, Naoki, Moreau, Philippe, Kaufman, Jonathan L., Krevvata, Maria, Chiu, Christopher, Qin, Xiang, Okonkwo, Linda, Trivedi, Sonali, Ukropec, Jon, Qi, Ming, San-Miguel, Jesus

“…In POLLUX, daratumumab (D) plus lenalidomide/dexamethasone (Rd) reduced the risk of disease progression or death by 63% and increased the overall response rate…”
Get full text

Medical and mental health implications of gestational surrogacy by Yau, Annie, Friedlander, Rachel L., Petrini, Allison, Holt, Mary Catherine, White, Darrell E., Shin, Joseph, Kalantry, Sital, Spandorfer, Steven

“…Gestational surrogacy in the United States has quadrupled since 1999, but to date, only a few states explicitly permit compensated gestational surrogacy…”
Get full text

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial by Lonial, Sagar, Prof, Weiss, Brendan M, Prof, Usmani, Saad Z, Prof, Singhal, Seema, Prof, Chari, Ajai, Prof, Bahlis, Nizar J, Prof, Belch, Andrew, Prof, Krishnan, Amrita, Prof, Vescio, Robert A, Prof, Mateos, Maria Victoria, Prof, Mazumder, Amitabha, Prof, Orlowski, Robert Z, Prof, Sutherland, Heather J, Prof, Bladé, Joan, Prof, Scott, Emma C, Prof, Oriol, Albert, MD, Berdeja, Jesus, MD, Gharibo, Mecide, Prof, Stevens, Don A, MD, LeBlanc, Richard, Prof, Sebag, Michael, Prof, Callander, Natalie, Prof, Jakubowiak, Andrzej, Prof, White, Darrell, Prof, de la Rubia, Javier, Prof, Richardson, Paul G, Prof, Lisby, Steen, MD, Feng, Huaibao, PhD, Uhlar, Clarissa M, PhD, Khan, Imran, MD, Ahmadi, Tahamtan, MD, Voorhees, Peter M, Prof

“…Summary Background New treatment options are needed for patients with multiple myeloma that is refractory to proteasome inhibitors and immunomodulatory drugs…”
Get full text

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma by Facon, Thierry, Venner, Christopher P., Bahlis, Nizar J., Offner, Fritz, White, Darrell J., Karlin, Lionel, Benboubker, Lotfi, Rigaudeau, Sophie, Rodon, Philippe, Voog, Eric, Yoon, Sung-Soo, Suzuki, Kenshi, Shibayama, Hirohiko, Zhang, Xiaoquan, Twumasi-Ankrah, Philip, Yung, Godwin, Rifkin, Robert M., Moreau, Philippe, Lonial, Sagar, Kumar, Shaji K., Richardson, Paul G., Rajkumar, S. Vincent

“…Continuous lenalidomide-dexamethasone (Rd)-based regimens are among the standards of care in transplant-ineligible newly diagnosed multiple myeloma (NDMM)…”
Get full text

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma by Benboubker, Lotfi, Dimopoulos, Meletios A, Dispenzieri, Angela, Catalano, John, Belch, Andrew R, Cavo, Michele, Pinto, Antonello, Weisel, Katja, Ludwig, Heinz, Bahlis, Nizar, Banos, Anne, Tiab, Mourad, Delforge, Michel, Cavenagh, Jamie, Geraldes, Catarina, Lee, Je-Jung, Chen, Christine, Oriol, Albert, de la Rubia, Javier, Qiu, Lugui, White, Darrell J, Binder, Daniel, Anderson, Kenneth, Fermand, Jean-Paul, Moreau, Philippe, Attal, Michel, Knight, Robert, Chen, Guang, Van Oostendorp, Jason, Jacques, Christian, Ervin-Haynes, Annette, Avet-Loiseau, Hervé, Hulin, Cyrille, Facon, Thierry

“…In patients ineligible for transplantation, the combination of lenalidomide and dexamethasone with lenalidomide maintenance until disease progression achieved…”
Get full text

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma by Facon, Thierry, Dimopoulos, Meletios A., Dispenzieri, Angela, Catalano, John V., Belch, Andrew, Cavo, Michele, Pinto, Antonello, Weisel, Katja, Ludwig, Heinz, Bahlis, Nizar J., Banos, Anne, Tiab, Mourad, Delforge, Michel, Cavenagh, Jamie D., Geraldes, Catarina, Lee, Je-Jung, Chen, Christine, Oriol, Albert, De La Rubia, Javier, White, Darrell, Binder, Daniel, Lu, Jin, Anderson, Kenneth C., Moreau, Philippe, Attal, Michel, Perrot, Aurore, Arnulf, Bertrand, Qiu, Lugui, Roussel, Murielle, Boyle, Eileen, Manier, Salomon, Mohty, Mohamad, Avet-Loiseau, Herve, Leleu, Xavier, Ervin-Haynes, Annette, Chen, Guang, Houck, Vanessa, Benboubker, Lotfi, Hulin, Cyrille

“…This FIRST trial final analysis examined survival outcomes in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM) treated with…”
Get full text

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX by Dimopoulos, Meletios A, San-Miguel, Jesus, Belch, Andrew, White, Darrell, Benboubker, Lotfi, Cook, Gordon, Leiba, Merav, Morton, James, Ho, P Joy, Kim, Kihyun, Takezako, Naoki, Moreau, Philippe, Kaufman, Jonathan L, Sutherland, Heather J, Lalancette, Marc, Magen, Hila, Iida, Shinsuke, Kim, Jin Seok, Prince, H Miles, Cochrane, Tara, Oriol, Albert, Bahlis, Nizar J, Chari, Ajai, O' Rourke, Lisa, Wu, Kaida, Schecter, Jordan M, Casneuf, Tineke, Chiu, Christopher, Soong, David, Sasser, A Kate, Khokhar, Nushmia Z, Avet-Loiseau, Hervé, Usmani, Saad Z

“…In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly reduced risk of progression/death versus lenalidomide/dexamethasone alone in…”
Get full text

Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR by Dimopoulos, Meletios, Siegel, David, White, Darrell J., Boccia, Ralph, Iskander, Karim S., Yang, Zhao, Kimball, Amy S., Mezzi, Khalid, Ludwig, Heinz, Niesvizky, Ruben

“…In ENDEAVOR, carfilzomib (56 mg/m2) and dexamethasone (Kd56) demonstrated longer progression-free survival (PFS) over bortezomib and dexamethasone (Vd) in…”
Get full text

Matching-adjusted indirect comparison of phase 3 clinical trial outcomes of OC-01 (varenicline solution) nasal spray and lifitegrast 5% ophthalmic solution for the treatment of dry eye disease by White, Darrell E, Hendrix, Laura H, Sun, Lucille, Tam, Iris, Macsai, Marian, Gibson, Andrea A

“…Matching-adjusted indirect comparison (MAIC) is a methodology for cross-study comparisons after adjusting for baseline characteristic imbalances. It is a…”
Get full text

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study by Dimopoulos, Meletios A., Lonial, Sagar, White, Darrell, Moreau, Philippe, Weisel, Katja, San-Miguel, Jesus, Shpilberg, Ofer, Grosicki, Sebastian, Špička, Ivan, Walter-Croneck, Adam, Magen, Hila, Mateos, Maria-Victoria, Belch, Andrew, Reece, Donna, Beksac, Meral, Spencer, Andrew, Oakervee, Heather, Orlowski, Robert Z., Taniwaki, Masafumi, Röllig, Christoph, Einsele, Hermann, Matsumoto, Morio, Wu, Ka Lung, Anderson, Kenneth C., Jou, Ying-Ming, Ganetsky, Alex, Singhal, Anil K., Richardson, Paul G.

“…Prolonging overall survival (OS) remains an unmet need in relapsed or refractory multiple myeloma (RRMM). In ELOQUENT-2 (NCT01239797), elotuzumab plus…”
Get full text

Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma by White, Darrell, Kassim, Adetola, Bhaskar, Birbal, Yi, Jing, Wamstad, Karen, Paton, Virginia E.

“…BACKGROUND. Newer systemic therapies have significantly advanced the treatment of multiple myeloma, but additional agents are needed. Bortezomib is a…”
Get full text

Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma by Usmani, Saad Z, Nahi, Hareth, Legiec, Wojciech, Grosicki, Sebastian, Vorobyev, Vladimir, Spicka, Ivan, Hungria, Vania, Korenkova, Sibirina, Bahlis, Nizar J, Flogegard, Max, Bladé, Joan, Moreau, Philippe, Kaiser, Martin, Iida, Shinsuke, Laubach, Jacob, Magen, Hila, Cavo, Michele, Hulin, Cyrille, White, Darrell, De Stefano, Valerio, Lantz, Kristen, O'Rourke, Lisa, Heuck, Christoph, Delioukina, Maria, Qin, Xiang, Nnane, Ivo, Qi, Ming, Mateos, Maria-Victoria

“…In the primary analysis of the phase III COLUMBA study, daratumumab by subcutaneous administration (DARA SC) demonstrated non-inferiority to intravenous…”
Get full text

Treatment Satisfaction Among Patients Using Anti-Inflammatory Topical Medications for Dry Eye Disease by White, Darrell E, Zhao, Yang, Jayapalan, Hemalatha, Machiraju, Pattabhi, Periyasamy, Ramu, Ogundele, Abayomi

“…To assess patient satisfaction among current and former users of the anti-inflammatory topical medications, cyclosporine A 0.05% (CYC) and lifitegrast 5.0%…”
Get full text

Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma by White, Darrell, Schiller, Gary J, Madan, Sumit, Lentzsch, Suzanne, Chubar, Evgeni, Lavi, Noa, Van Domelen, Dane R, Bentur, Ohad S, Baljevic, Muhamed

“…To identify the optimal dose of selinexor in combination with pomalidomide and dexamethasone (SPd). An analysis of efficacy and safety of 2 once-weekly…”
Get full text

The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database by Cherniawsky, Hannah M., Kukreti, Vishal, Reece, Donna, Masih-Khan, Esther, McCurdy, Arleigh, Jimenez-Zepeda, Victor H., Sebag, Michael, Song, Kevin, White, Darrell, Stakiw, Julie, LeBlanc, Richard, Reiman, Anthony, Aslam, Muhammad, Louzada, Martha, Kotb, Rami, Gul, Engin, Atenafu, Eshetu, Venner, Christopher P.

Get full text

Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial by McCurdy, Arleigh, Reece, Donna, Louzada, Martha L., White, Darrell, Parkin, Stephen, Chu, Michael P., Kotb, Rami, Mian, Hira, Othman, Ibraheem, Su, Jiandong, Khan, Aniba, Gul, Engin, Trudel, Suzanne

“…Given the early use of triplet and quadruplet regimens, most patients with multiple myeloma (MM) will be exposed and/or refractory to PIs, IMiDs, and anti-CD38…”
Get full text

Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study by Richardson, Paul G, Prof, Jagannath, Sundar, Prof, Moreau, Philippe, Prof, Jakubowiak, Andrzej J, Prof, Raab, Marc S, MD, Facon, Thierry, Prof, Vij, Ravi, Prof, White, Darrell, Prof, Reece, Donna E, MD, Benboubker, Lotfi, MD, Zonder, Jeffrey, MD, Tsao, L Claire, PhD, Anderson, Kenneth C, Prof, Bleickardt, Eric, MD, Singhal, Anil K, MD, Lonial, Sagar, Prof

“…Summary Background Elotuzumab, an immunostimulatory monoclonal antibody targeting signalling lymphocytic activation molecule (SLAM) family member 7 (SLAMF7),…”
Get full text

Chronic Conjunctivitis From a Retained Contact Lens by Arshad, Jawad I., Saud, Asma, White, Darrell E., Afshari, Natalie A., Sayegh, Rony R.

“…PURPOSE:To help clinicians diagnose and manage unilateral recalcitrant chronic bacterial conjunctivitis secondary to a retained soft contact lens and describe…”
Get full text

Tear Film Hyperosmolarity is Associated with Increased Variation of Light Scatter Following Cataract Surgery by Sullivan, Benjamin D, Palazón de la Torre, Marta, Yago, Ines, Duarte, Raúl, Schallhorn, Julie M, Nijm, Lisa M, White, Darrell E, Berg, Michael S, Artal, Pablo

“…To study the association between tear film hyperosmolarity and ocular light scatter in a cataract surgery population. Contiguous, 20-second objective scatter…”
Get full text

Bortezomib Is Active in Patients With Untreated or Relapsed Waldenström's Macroglobulinemia: A Phase II Study of the National Cancer Institute of Canada Clinical Trials Group by CHEN, Christine I, KOUROUKIS, C. Tom, WHITE, Darrell, VORALIA, Michael, STADTMAUER, Edward, STEWART, A. Keith, WRIGHT, John J, POWERS, Jean, WALSH, Wendy, EISENHAUER, Elizabeth

“…To evaluate the efficacy and toxicity of single-agent bortezomib in Waldenström's macroglobulinemia (WM). Symptomatic WM patients, untreated or previously…”
Get full text